Thomas Meyer

Summary

Affiliation: University Medical Center Hamburg-Eppendorf
Country: Germany

Publications

  1. doi request reprint Resiquimod, a topical drug for viral skin lesions and skin cancer
    Thomas Meyer
    University of Hamburg, Institute of Medical Microbiology, Virology and Hygiene, University Hospital Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Expert Opin Investig Drugs 22:149-59. 2013
  2. ncbi request reprint Clinical investigations of Toll-like receptor agonists
    Thomas Meyer
    University of Hamburg, University Hospital Hamburg Eppendorf, Institute of Medical Microbiology, Virology and Hygiene, Martinistrasse 52, 20246 Hamburg, Germany
    Expert Opin Investig Drugs 17:1051-65. 2008
  3. doi request reprint [Diagnosis and treatment of Chlamydia trachomatis infections]
    T Meyer
    Institut fur Medizinische Mikrobiologie, Virologie und Hygiene, Universitätsklinikum Hamburg Eppendorf UKE, Martinistr 52, 20246, Hamburg, Deutschland
    Hautarzt 63:16-23. 2012
  4. ncbi request reprint Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
    Doriano Fabbro
    Department of Oncology, Novartis Pharma Inc, WKL 125 4 10, CH 4002, Basel, Switzerland
    Pharmacol Ther 93:79-98. 2002
  5. ncbi request reprint A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses
    Eggert Stockfleth
    Department of Dermatology, University of Kiel, Germany
    Arch Dermatol 138:1498-502. 2002

Collaborators

  • Lars E French
  • Doriano Fabbro
  • Eggert Stockfleth
  • Jurgen Mestan
  • Heinz Fretz
  • Stephan Ruetz
  • Gabriele Fendrich
  • Janis Liebetanz
  • Giorgio Caravatti
  • Sandra W Cowan-Jacob
  • Terence O'Reilly
  • Bhabatosh Chaudhuri
  • Enno Christophers
  • Bernd Benninghoff
  • Latza Papadopoulos
  • Claas Ulrich
  • Stuart Salasche
  • Peter Traxler
  • Pascal Furet
  • Jurg Zimmermann
  • Elisabeth Buchdunger
  • Paul W Manley

Detail Information

Publications5

  1. doi request reprint Resiquimod, a topical drug for viral skin lesions and skin cancer
    Thomas Meyer
    University of Hamburg, Institute of Medical Microbiology, Virology and Hygiene, University Hospital Hamburg Eppendorf, Martinistr 52, 20246 Hamburg, Germany
    Expert Opin Investig Drugs 22:149-59. 2013
    ..Resiquimod is an immune response modifier which stimulates cells through a toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune responses that are effective against viral and tumor lesions...
  2. ncbi request reprint Clinical investigations of Toll-like receptor agonists
    Thomas Meyer
    University of Hamburg, University Hospital Hamburg Eppendorf, Institute of Medical Microbiology, Virology and Hygiene, Martinistrasse 52, 20246 Hamburg, Germany
    Expert Opin Investig Drugs 17:1051-65. 2008
    ..Ligand binding to TLR results in activation of cellular signaling pathways that regulate expression of genes involved in inflammation and immunity...
  3. doi request reprint [Diagnosis and treatment of Chlamydia trachomatis infections]
    T Meyer
    Institut fur Medizinische Mikrobiologie, Virologie und Hygiene, Universitätsklinikum Hamburg Eppendorf UKE, Martinistr 52, 20246, Hamburg, Deutschland
    Hautarzt 63:16-23. 2012
    ..Alternatively erythromycin, ofloxacin and levofloxacin can be used. Persistent infections usually require treatment for longer periods or by using combinations of different antibiotics...
  4. ncbi request reprint Protein kinases as targets for anticancer agents: from inhibitors to useful drugs
    Doriano Fabbro
    Department of Oncology, Novartis Pharma Inc, WKL 125 4 10, CH 4002, Basel, Switzerland
    Pharmacol Ther 93:79-98. 2002
    ..Phase I/II studies demonstrated that STI571 is well tolerated, and that it showed promising hematological and cytogenetic responses in CML and clinical responses in the c-Kit-driven gastrointestinal tumors...
  5. ncbi request reprint A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses
    Eggert Stockfleth
    Department of Dermatology, University of Kiel, Germany
    Arch Dermatol 138:1498-502. 2002
    ..Several case studies published recently have indicated that 5% imiquimod cream, currently licensed for the treatment of genital warts, may be an effective treatment for AK...